MRNAHealthcare · BiotechnologyThe 23 Wall Street analysts covering Moderna, Inc. hold a median 12-month price target of $45 — -28.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 15 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Moderna, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.
Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MRNA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −28.9% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2026 | Citigroup | Maintains | Neutral | $41 → $60 |
| 21 July 2026 | Goldman Sachs | Maintains | Neutral | — |
| 21 July 2026 | Goldman Sachs | Maintains | Neutral | $49 → $67 |
| 8 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 8 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $33 → $39 |
| 7 July 2026 | B of A Securities | Maintains | Underperform | $34 → $38 |
| 7 July 2026 | B of A Securities | Maintains | Underperform | — |
| 7 July 2026 | RBC Capital | Maintains | Sector Perform | — |
| 7 July 2026 | RBC Capital | Maintains | Sector Perform | $38 → $45 |
| 26 June 2026 | Piper Sandler | Maintains | Overweight | — |
| 8 June 2026 | B of A Securities | Maintains | Underperform | — |
| 4 May 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 4 May 2026 | Goldman Sachs | Maintains | Neutral | — |
| 4 May 2026 | RBC Capital | Maintains | Sector Perform | — |
| 4 May 2026 | UBS | Maintains | Neutral | — |
| 2 Apr 2026 | Barclays | Maintains | Equal-Weight | — |
| 23 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Feb 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 17 Feb 2026 | Goldman Sachs | Maintains | Neutral | — |
| 17 Feb 2026 | RBC Capital | Maintains | Sector Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MRNA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 32% of US stocks
Cheaper than 13% of US stocks
Cheaper than 29% of US stocks
Cheaper than 84% of US stocks
Higher than 32% of US stocks
Higher than 41% of US stocks
Higher than 43% of US stocks
Higher than 7% of US stocks
Higher than 4% of US stocks
Higher than 24% of US stocks
Higher than 24% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Moderna, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Moderna held its Q2 earnings call, keeping its 2026 growth target intact while lowering its cost guidance. The company is advancing its flu, oncology, and rare-disease programs toward key milestones.
Why it matters — MRNA watchers would care because the company is balancing cost reductions with progress across its pipeline, which could shape its near-term outlook.
Barron's reports that positive readouts in cancer and cardiac drug trials could keep the biotech and pharma rally going. The article sizes up the stakes for Merck, Moderna, Summit Therapeutics, and other companies. Moderna is among the companies examined in this context.
Why it matters — A Moderna watcher would care because the article flags that successful trial readouts in the sector, including Moderna's, could help sustain momentum for the company's stock.
The FDA approved Moderna's mFlusiva, the first mRNA-based flu vaccine, for adults aged 50 and older. Moderna expects the shot to be available soon at select retailers ahead of the fall vaccination season.
Why it matters — This approval marks Moderna's first FDA-approved mRNA flu vaccine, expanding its product portfolio beyond COVID-19 vaccines.
Moderna's shares, which traded as high as $497 in 2021, now stand at $55.12 and are trending lower despite the FDA approving the company's flu vaccine. The news item describes the stock's pullback as flashing an "intriguing 'buy the dip' signal."
Why it matters — A Moderna watcher would care because the stock is falling to multi-year lows even as it gains a new regulatory approval, and the article suggests investors are watching this drop as a potential entry point.
The FDA approved Moderna's mFLUSIVA (mRNA-1010), a seasonal influenza vaccine, for use in all adults aged 50 and older. This marks FDA approval for a Moderna vaccine targeting a disease beyond COVID.
Why it matters — The approval expands Moderna's approved vaccine portfolio beyond its COVID franchise, broadening its commercial reach into the seasonal flu market.
The 23 Wall Street analysts covering Moderna, Inc. have a median 12-month price target of $45, with estimates ranging from $25 to $79. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 23 analysts covering Moderna, Inc., 4 rate it a Buy, 16 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Moderna, Inc. 75 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Moderna, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).
No one can know that. What the data says: the median 12-month target from 23 analysts implies -28.9% from the last close, and Ticker Nerd's factor model ranks Moderna, Inc. 75 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Moderna, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $79 over the next 12 months.
Moderna, Inc. returned +137.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Moderna, Inc. is a biotechnology company focused on messenger RNA (mRNA) medicines and vaccines.
The most recent item we track (Zacks Investment Research, 7 Aug 2026): "Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones". Moderna held its Q2 earnings call, keeping its 2026 growth target intact while lowering its cost guidance. The company is advancing its flu, oncology, and rare-disease programs toward key milestones.
Moderna, Inc. is a biotechnology company focused on messenger RNA (mRNA) medicines and vaccines. Its portfolio centers on products for respiratory and infectious diseases, including COVID-19 and RSV vaccines, alongside a pipeline that extends into oncology, rare diseases, autoimmune disorders, and other therapeutic areas. The company uses its mRNA platform to design medicines that instruct cells to produce proteins with preventive or therapeutic potential, making it an important developer in modern biopharmaceutical research. Moderna, Inc. also maintains integrated manufacturing capabilities and commercial operations that support the development, production, and distribution of its current products and clinical programs. Headquartered in Cambridge, Massachusetts, and founded in 2010, Moderna, Inc. plays a notable role in advancing mRNA-based treatments and vaccines across global healthcare markets.
CEO Mr. Stéphane Bancel M.B.A. · 4,700 employees · United States · https://www.modernatx.com